Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Gepubliceerd in:
Huisartsgeneeskundige oncologie hoofdstuk lezen eerste hoofdstuk lezen

2014 | OriginalPaper | Hoofdstuk

7. Targeted therapieën

Auteurs : Epie Boven, Gert Jan Ossenkoppele

Gepubliceerd in: Ontwikkelingen in de oncologie

Uitgeverij: Bohn Stafleu van Loghum

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Inleiding

De kennis over de ontwikkeling en pathofysiologie van maligniteiten is zodanig toegenomen dat men sinds enige jaren geneesmiddelen ontwikkelt die aangrijpen op specifieke pathologische eigenschappen van de kankercel. Dit type behandelingen, die men wel doelgerichte of targeted therapieën noemt, behoren inmiddels tot de standaardbehandeling van veel solide en hematologische tumoren. Tabel 7.1 geeft een overzicht van de nieuwe middelen die daarbij worden gebruikt. Targeted therapieën zijn geen klassieke chemo- of hormoontherapieën, maar kunnen wel degelijk ernstige bijwerkingen hebben.
vorige hoofdstuk Bevolkingsonderzoek borstkanker
volgende hoofdstuk HIPEC, een nieuwe chirurgische techniek
Literatuur
1.
Cilloni D, Saglio G. CML: A model for targeted therapy. Best Pract Res Clin Haematol 2009;22:285–94.PubMedCrossRef
2.
3.
Migkou M, Dimopoulos MA, Gavriatopoulou M, Terpos E. Applications of monoclonal antibodies for the treatment of hematological malignancies. Expert Opin Biol Ther 2009;9:207–220.PubMedCrossRef
4.
5.
Van Meerten T, Hagenbeek A. CD20-targeted therapy: A breakthrough in the treatment of non-Hodgkin’s lymphoma. Neth J Med. 2009;67:251–9.PubMed
6.
Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 2009;23:2222–32.PubMedCentralPubMedCrossRef
7.
Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia. 2009;23:1964–79.PubMedCrossRef
8.
Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550–65.PubMedCrossRef
9.
Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 2010;277:301–8.PubMedCrossRef
10.
Okamoto I. Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. FEBS J 2010;277:309–15.PubMedCrossRef
11.
12.
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21–8.PubMedCrossRef
13.
Rukazenkov Y, Speake G, Marshall G, Anderton J, Davies BR, Wilkinson RW, et al. Epidermal growth factor receptor tyrosine kinase inhibitors. Similar but different? Anticancer Drugs 2009;20:856–66.PubMedCrossRef
14.
Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010;28:357–60.PubMedCrossRef
15.
Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies. Canadian recommendations. Current Oncol 2009;16:16–26.
16.
Pérez-Soler R, Delord JP, Halpern A, Kelly K, Sureda BM, Von Pawel J, et al. HER1/EGFR inhibitor-associated rash; future directions for management and investigation outcomes from HER1/EGFR inhibitor rash management forum. Oncologist 2005;10:345–56.PubMedCrossRef
17.
Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009;10:470–81.PubMedCrossRef
18.
Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009;27:5838–47.PubMedCrossRef
19.
Tevaarwerk AJ, Kolesar JM. Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther 2009;31:2332–48.PubMedCrossRef
20.
21.
Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;8:507–18.CrossRef
22.
Patel NS, Muneer A, Blick C, Arya M, Harris AL. Targeting vascular endothelial growth factor in renal cell carcinoma. Tumor Biol 2009;30:292–9.CrossRef
23.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon-alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–24.PubMedCrossRef
24.
Mihály Z, Sztupinszki Z, Surowiak P, Györffy B. A comprehensive overview of targeted therapy in metastatic renal cell carcinoma. Curr Cancer Drug Targets 2012;12:857-872. 24.Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010;102:8–18.CrossRef
25.
Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011;30:134–141.PubMedCentralPubMedCrossRef
26.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507–2516.PubMedCentralPubMedCrossRef
27.
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–723.PubMedCentralPubMedCrossRef
28.
Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283–9.PubMedCentralPubMedCrossRef
29.
Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 2012;366:520–529.PubMedCrossRef
30.
Aprile G, Mazzer M, Moroso S, Puglisi F. Pharmacology and therapeutic efficacy of capecitabine. Focus on breast and colorectal cancer. Anticancer Drugs 2009;20:217–29.PubMedCrossRef
31.
Comella P, Franco L, Casaretti R, De Portu S, Menditto E. Emerging role of capecitabine in gastric cancer. Pharmacotherapy 2009;29:318–30.PubMedCrossRef
32.
33.
O’Brien MER. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. Anticancer Drugs 2008;19:1–7.PubMedCrossRef
34.
Guarneri V, Piacentini F, Barbieri E, Conte PF. Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol 2010;117:152–8.PubMedCrossRef
35.
Gossage L, Eisen T. Targeting multiple kinase pathways. Change in paradigm. Clin Cancer Res 2010;16:1973–8.PubMedCrossRef
36.
Ellis LM, Hicklin DJ. Resistance to targeted therapies: Refining anticancer therapy in the era of molecular oncology. Clin Cancer Res 2009;15:7471–8.PubMedCrossRef
37.
Petrelli NJ, Winer EP, Brahmer J, Dubey S, Smith S, Thomas C, et al. Clinical cancer advances 2009: Major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J Clin Oncol 2009;27:6052–69.PubMedCrossRef
Metagegevens
Titel
Targeted therapieën
Auteurs
Epie Boven
Gert Jan Ossenkoppele
Copyright
2014
Uitgeverij
Bohn Stafleu van Loghum
Boek
Ontwikkelingen in de oncologie

Print ISBN: 978-90-368-0435-6

Elektronisch ISBN: 978-90-368-0436-3

Copyright: 2014

DOI
https://doi.org/10.1007/978-90-368-0436-3_7